FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2066438222> ?p ?o ?g. }

• W2066438222 abstract "Persistent immunosuppression despite viral suppression (immunovirological discordance, ID) has been associated with higher risk of AIDS and death, although the risk for AIDS seems to decrease with longer time of suppressed viral load (sVL). The impact of ID on a composite endpoint of AIDS/serious non-AIDS/death has not been thoroughly investigated. Patients in EuroSIDA starting ≥1 new antiretroviral drugs after January 2001, when CD4 was <200 cells/mm3 and VL >500 copies/mL, and who achieved a sVL ≤50 copies/mL within 1 year were included. Person-years of follow-up (PYFU) accrued from the date of sVL until the first of a new AIDS or severe non-AIDS (SNA) event or death, viral rebound >50 copies/mL (first of 2 consecutive values) or last visit. Rate ratios (RR) were calculated using Poisson regression according to whether or not patient's current CD4 count was still below 200 cells/mm3 (ID). Models were stratified according to whether or not persons were ART-naïve at baseline. Multivariable models included age, HBV/HCV status, mode of HIV transmission, race, cohort, anemia, diabetes, hypertension or current eGFR, current cART, number of previous antiretrovirals, and time to viral suppression. 994 patients satisfied the inclusion criteria and contributed 4520 PYFU. Median age was 41 (IQR 34–47) years and 72.8% were male. 36.5% of patients were ART-naïve and started a median of 3 (IQR 2–3) new drugs. 31 AIDS and 58 non-AIDS events occurred, and 31 patients died (7 due to AIDS, 24 due to SNA). The rate of the combined endpoint in patients with ID (50.3 per 1000 PYFU [95% CI 35.2–69.9]) was higher than in patients recovered from ID (22.1 [17.6–27.3], adjusted RR 2.08 [1.32–3.28]; table). This was similar regardless of whether or not people were ART-naïve before starting a new drug (interaction test p=0.47). In ID, rate was highest in the first 6 months of sVL (63.1 [33.6–107.9]) and declined thereafter (month 6–12: 60.5 [26.1–119.2],>12 months: 39.8 [22.2–65.6], adjusted RR compared to month 0–6 0.52 [0.24–1.13]). In analyses with endpoints AIDS/death due to AIDS and SNA/death due to SNA separately, the adjusted RR of ID vs. non ID was 4.11 ([1.76–9.60]; p=0.001) and 1.46 ([0.81–2.61]; p=0.207), respectively. Exposure No.events PYFU Rate (95%CI) Crude RR (95%CI) Adjusted**RR (95%CI) All patients No Discordance 84 3805 22.1 (17.6–27.3) 1 1 Discordance 36 716 50.3 (35.2–69.6) 2.28 (1.54–3.38) 2.08 (1.32–3.28) ART-naïve* patients No Discordance 29 1324 21.9 (14.7–31.5) 1 1 Discordance 9 228 39.5 (18.1–74.9) 1.80 (0.84–3.85) 1.87 (0.81–4.33) ART-treated* patients No Discordance 55 2481 22.2 (16.7–28.9) 1 1 Discordance 27 488 55.4 (36.5–80.6) 2.50 (1.67–3.97) 1.89 (1.08–3.32) * before starting a new antiretroviral drug according to the inclusion criteria, p(test for interaction):0.47 ** adjusted for smoking, HBV/HCV coinfection, transmission risk, race, cohort, current cART, change of ART before viral suppression, time to viral suppression, presence of diabetes, hypertension, anemia, current eGFR <90, CD4 nadir, CD4 count and viral load at baseline. ID is a risk factor for clinical disease progression particularly related to AIDS events. In patients with ID, we found a trend for a declining incidence of events with longer periods of sVL, suggesting that sustained viral suppression might be of benefit." @default.
• W2066438222 created "2016-06-24" @default.
• W2066438222 creator A5001375239 @default.
• W2066438222 creator A5015181430 @default.
• W2066438222 creator A5027160828 @default.
• W2066438222 creator A5047438814 @default.
• W2066438222 creator A5074980560 @default.
• W2066438222 creator A5080120008 @default.
• W2066438222 creator A5084125980 @default.
• W2066438222 date "2012-11-11" @default.
• W2066438222 modified "2023-09-26" @default.
• W2066438222 title "Immuno-virological discordance is associated with a higher frequency of AIDS, severe non-AIDS, and death" @default.
• W2066438222 doi "https://doi.org/10.7448/ias.15.6.18194" @default.
• W2066438222 hasPublicationYear "2012" @default.
• W2066438222 type Work @default.
• W2066438222 sameAs 2066438222 @default.
• W2066438222 citedByCount "0" @default.
• W2066438222 crossrefType "journal-article" @default.
• W2066438222 hasAuthorship W2066438222A5001375239 @default.
• W2066438222 hasAuthorship W2066438222A5015181430 @default.
• W2066438222 hasAuthorship W2066438222A5027160828 @default.
• W2066438222 hasAuthorship W2066438222A5047438814 @default.
• W2066438222 hasAuthorship W2066438222A5074980560 @default.
• W2066438222 hasAuthorship W2066438222A5080120008 @default.
• W2066438222 hasAuthorship W2066438222A5084125980 @default.
• W2066438222 hasConcept C126322002 @default.
• W2066438222 hasConcept C142462285 @default.
• W2066438222 hasConcept C187212893 @default.
• W2066438222 hasConcept C203014093 @default.
• W2066438222 hasConcept C2778248108 @default.
• W2066438222 hasConcept C2780252810 @default.
• W2066438222 hasConcept C2908647359 @default.
• W2066438222 hasConcept C3013748606 @default.
• W2066438222 hasConcept C50382708 @default.
• W2066438222 hasConcept C71924100 @default.
• W2066438222 hasConcept C72563966 @default.
• W2066438222 hasConcept C73269764 @default.
• W2066438222 hasConcept C99454951 @default.
• W2066438222 hasConceptScore W2066438222C126322002 @default.
• W2066438222 hasConceptScore W2066438222C142462285 @default.
• W2066438222 hasConceptScore W2066438222C187212893 @default.
• W2066438222 hasConceptScore W2066438222C203014093 @default.
• W2066438222 hasConceptScore W2066438222C2778248108 @default.
• W2066438222 hasConceptScore W2066438222C2780252810 @default.
• W2066438222 hasConceptScore W2066438222C2908647359 @default.
• W2066438222 hasConceptScore W2066438222C3013748606 @default.
• W2066438222 hasConceptScore W2066438222C50382708 @default.
• W2066438222 hasConceptScore W2066438222C71924100 @default.
• W2066438222 hasConceptScore W2066438222C72563966 @default.
• W2066438222 hasConceptScore W2066438222C73269764 @default.
• W2066438222 hasConceptScore W2066438222C99454951 @default.
• W2066438222 hasIssue "6(Suppl 4)" @default.
• W2066438222 hasLocation W20664382221 @default.
• W2066438222 hasOpenAccess W2066438222 @default.
• W2066438222 hasPrimaryLocation W20664382221 @default.
• W2066438222 hasRelatedWork W1966492635 @default.
• W2066438222 hasRelatedWork W2038756830 @default.
• W2066438222 hasRelatedWork W2153563100 @default.
• W2066438222 hasRelatedWork W2374911868 @default.
• W2066438222 hasRelatedWork W2603773853 @default.
• W2066438222 hasRelatedWork W2739625147 @default.
• W2066438222 hasRelatedWork W2967572767 @default.
• W2066438222 hasRelatedWork W2973613259 @default.
• W2066438222 hasRelatedWork W3024203344 @default.
• W2066438222 hasRelatedWork W3138630222 @default.
• W2066438222 hasVolume "15" @default.
• W2066438222 isParatext "false" @default.
• W2066438222 isRetracted "false" @default.
• W2066438222 magId "2066438222" @default.
• W2066438222 workType "article" @default.